MIDDLE EAST & NORTH AFRICA

We supply globally branded pharmaceutical products as well as local brands into multiple territories within MENA. Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2017 financial year.

Key Countries

Algeria
Egypt
Morocco
Saudi Arabia
United Arab Emirates

Contribution to Group revenue

Revenue contribution - by therapeutic category

The MENA pharmaceutical sector grew 7,9% and was valued at approximately USD29,3 billion for the year to 30 June 2017.
Growth was largely driven by Algeria and Egypt whose value grew in double digits to USD4,8 billion and USD4,6 billion respectively.

Source: June 2017 IMS

STATISTICS

Number of products launched:

Nil

(2016: nil)

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:

0 – 2 years

USD158 million

3 – 5 years

USD9 million

Number of product recalls:

Nil

(2016: nil)

Average staff turnover:

18,7%

(2016: 23,5%)

Number of work-related fatalities:

Nil

(2016: nil)

Number of permanent employees:

Revenue – R’billion	2017	2016 (CER)*	% change
Total	1,1	0,7	36
Anaesthetics	0,2	–	>100
Thrombosis	0,2	0,1	25
High Potency & Cytotoxics	0,3	0,2	4
Other Commercial Pharmaceutical Brands	0,4	0,4	5

* Constant exchange rate: FY16 restated at FY17 average exchange rates. Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.